RxDoctor Payments Data

Peter Fernandez, MD

Interventional Pain Medicine · Sarasota, FLNPI 1457560294

Payments from drug & device makers

$10,176in general payments, 2019–2025

Across 272 payments — averaging $37.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertiflex, Inc.$2K
  • Abbott$2K
  • Vertos Medical, Inc.$1K
  • Boston Scientific$1K
  • AbbVie$823
  • Relievant Medsystems, Inc.$392
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$3,61536%
  • Food & beverage$6,56164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,176 in reported general payments places this provider in the 65th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$994,087
Medicare patients
869
Services billed
37,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate77$45,109
RoxicodoneOxycodone Hcl26$22,152
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen637$15,926
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen451$15,511
Oxymorphone Hcl ErOxymorphone Hcl11$14,750
Tramadol Hcl ErTramadol Hcl187$9,522
Oxycodone Hcl437$8,677
MovantikNaloxegol Oxalate14$6,420
Morphine Sulfate ErMorphine Sulfate163$5,459
Pentazocine-Naloxone HclPentazocine Hcl/Naloxone Hcl15$4,814
Buprenorphine Hcl19$4,421
Gabapentin348$3,718
Fentanyl23$3,630
Diclofenac Sodium242$3,044
Pregabalin172$3,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$76$45,10977 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →